Pharmaceutical Business review

Lonza to invest $7.95m in Meta metaldehyde formulation plant

The company expects to start operations in the new formulation plant in the second half of 2012.

Lonza Nutrition business unit head Roman Quinter said by developing ready-made slug pellets, they are building up a distinct and independent position and will be able to create the necessary proximity to the market to drive innovations.

"With our formulation plant, we are establishing quality and safety standards in the molluscicide business and complying with stricter regulatory and environmental requirements," Quinter said.